Results 11 to 20 of about 327,068 (394)

Benralizumab in severe eosinophilic asthma in real life: confirmed effectiveness and contrasted effect on sputum eosinophilia versus exhaled nitric oxide fraction - PROMISE. [PDF]

ERJ Open Res, 2023
Background Randomised controlled trials have shown that benralizumab, an anti-interleukin-5 receptor monoclonal antibody, reduces exacerbations and oral corticosteroid dose and improves asthma control and lung function in severe eosinophilic asthma.
Schleich F, Moermans C, Seidel L, Kempeneers C, Louis G, Rogister F, Tombu S, Pottier L, Poirrier AL, Ziant S, Henket M, Sanchez C, Paulus V, Guissard F, Donneau AF, Louis R.   +15 more
europepmc   +2 more sources

Treating Acute Severe Eosinophilic Asthma with IL-5 Inhibitors in ICU [PDF]

Case Reports in Pulmonology, 2022
Introduction. About 10% of the 300 million people worldwide who suffer from asthma have a severe disease that is uncontrolled despite treatment with inhaled corticosteroids and long-acting beta agonists.
Nicolas Barbarot, Emmanuelle Nourry, Nicolas Massart, François Legay, Matthieu Debarre, Pierre Fillatre, Eric Magalhaes, Arnaud Mari, Julien Wallois, Eric Briens, Stéphane Jouneau   +10 more
doaj   +2 more sources

Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study

Therapeutic Advances in Respiratory Disease, 2021
Background: Severe eosinophilic asthma is frequently associated to chronic rhinosinusitis and nasal polyposis (CRSwNP) that contribute to poor asthma control.
Aikaterini Detoraki, Eugenio Tremante, Maria D’Amato, Cecilia Calabrese, Claudia Casella, Mauro Maniscalco, Remo Poto, Raffaele Brancaccio, Matilde Boccia, Maria Martino, Clara Imperatore, Giuseppe Spadaro   +11 more
doaj   +2 more sources

Reliability, Satisfaction and Effectiveness of Benralizumab Home Self-Administration in Patients with Severe Eosinophilic Asthma in Real-World Practice: The Auto-Benra Study

Journal of Asthma and Allergy, 2022
Ismael García-Moguel,1,2 Ana Rosado,3 Aída Gómez-Cardeñosa,4,5 Mar Gandolfo-Cano,6,7 Teresa Robledo Echarren,8 Maria del Mar Moro Moro,9 Mª del Mar Reaño Martos,10 Rafael Pineda-Pineda,11 Marcela Valverde-Monge,4,5 Cristina Martin-Arriscado Arroba,12 ...
García-Moguel I, Rosado A, Gómez-Cardeñosa A, Gandolfo-Cano M, Robledo Echarren T, Moro Moro MDM, Reaño Martos MDM, Pineda-Pineda R, Valverde-Monge M, Martin-Arriscado Arroba C, Domínguez-Ortega J   +10 more
doaj   +2 more sources

Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study. [PDF]

J Clin Med
Background: Benralizumab has been shown to restore good control of severe eosinophilic asthma (SEA). Robust data on benralizumab effectiveness over periods longer than 2 years are scarce.
Pini L, Bagnasco D, Beghè B, Braido F, Cameli P, Caminati M, Caruso C, Crimi C, Guarnieri G, Latorre M, Menzella F, Micheletto C, Vianello A, Visca D, Bondi B, El Masri Y, Giordani J, Mastrototaro A, Maule M, Pini A, Piras S, Zappa M, Senna G, Spanevello A, Paggiaro P, Blasi F, Canonica GW, On Behalf Of The Sani Study Group.   +27 more
europepmc   +2 more sources

Burden of asthma exacerbations and health care utilization in pediatric patients with asthma in the US and England [PDF]

Immunity, Inflammation and Disease, 2020
Background Data on asthma burden in pediatric patients are limited; this real‐world study investigated exacerbation frequency and health care resource utilization (HCRU) in pediatric asthma patients from the US and England.
Mugdha Gokhale, Takako Hattori, Lee Evitt, Warren Lenney, Beth Nordstrom, Jenna Collins, Anna Schultze, Melissa K. Van Dyke   +7 more
doaj   +2 more sources

Management of Severe Asthma in Eosinophilic Granulomatosis with Polyangiitis with Interleukin-5-Targeted Therapies: Current Status and Report of Two Cases [PDF]

Applied Sciences, 2022
Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic disorder characterized by peripheral eosinophilia, severe eosinophilic asthma, sinusitis, transient pulmonary infiltrates, and features of medium/small-vessel vasculitis.
Ciro Romano, Domenico Cozzolino, Ausilia Sellitto, Luca Rinaldi   +3 more
doaj   +3 more sources

Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme. [PDF]

Eur Respir J
Graphical abstract In this large, real-world programme, patients with severe eosinophilic asthma treated with benralizumab had substantial improvements in clinical outcomes, irrespective of previous biologic use and key clinical characteristics important
Jackson DJ, Pelaia G, Emmanuel B, Tran TN, Cohen D, Shih VH, Shavit A, Arbetter D, Katial R, Rabe APJ, Garcia Gil E, Pardal M, Nuevo J, Watt M, Boarino S, Kayaniyil S, Chaves Loureiro C, Padilla-Galo A, Nair P.   +18 more
europepmc   +2 more sources

Clinical Remission in Patients Affected by Severe Eosinophilic Asthma on Dupilumab Therapy: A Long-Term Real-Life Study. [PDF]

J Clin Med
Background. Nowadays, highly selective biological drugs offer the possibility of treating severe type 2 asthma. However, in the real-life setting, it is crucial to confirm the validity of the chosen biological treatment by evaluating the achievement of ...
Quarato CMI, Tondo P, Lacedonia D, Soccio P, Fuso P, Sabato E, Hoxhallari A, Foschino Barbaro MP, Scioscia G.   +8 more
europepmc   +2 more sources

Treatment with interleukin (IL)-5/IL-5 receptor antibodies in patients with severe eosinophilic asthma and COPD [PDF]

ERJ Open Research, 2022
Background Anti-eosinophilic therapy with interleukin-5/interleukin-5-receptor antibodies represents an established treatment for patients with severe eosinophilic asthma (SEA) but did not show clinical efficacy in patients with COPD.
Nora Drick, Jan Fuge, Benjamin Seeliger, Milan Speth, Jens Vogel‐Claussen, Tobias Welte, Hendrik Suhling   +6 more
openalex   +2 more sources